Literature DB >> 23433533

Surveillance of dalbavancin potency and spectrum in the United States (2012).

Ronald N Jones, Robert K Flamm, Helio S Sader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23433533     DOI： 10.1016/j.diagmicrobio.2013.01.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


× No keyword cloud information.
  12 in total

1.  Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

Authors:  David J Farrell; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

Review 3.  Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 4.  Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

5.  Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus In Vitro.

Authors:  Sarah E Hobdey; Eva J Katahira; Pamela Dockstader; Stephen M Davidson; Laura Bond; Devin D Bolz; Amy E Bryant; Dennis L Stevens
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.

Authors:  Laura M Koeth; Jeanna M DiFranco-Fisher; Sandra McCurdy
Journal:  J Vis Exp       Date:  2015-09-09       Impact factor: 1.355

Review 7.  Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Authors:  Sheena Ramdeen; Helen W Boucher
Journal:  Expert Opin Pharmacother       Date:  2015-08-04       Impact factor: 3.889

8.  Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors:  Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.

Authors:  Selma Tobudic; Christina Forstner; Heinz Burgmann; Heimo Lagler; Christoph Steininger; Ludwig Traby; Mathias G Vossen; Stefan Winkler; Florian Thalhammer
Journal:  Infection       Date:  2019-09-13       Impact factor: 3.553

Review 10.  Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

Authors:  Luis Buzón-Martín; I Zollner-Schwetz; Selma Tobudic; Emilia Cercenado; Jaime Lora-Tamayo
Journal:  Antibiotics (Basel)       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.